Journal Watch · Journal of Medicinal Chemistry · 2026
Discovery of Stable and Permeable <i>N</i>-Methylated Cyclic Peptides to Block the Endocytosis of GluA2 AMPAR for Ischemic Stroke Therapy.
Collectively, these findings establish <b>c10c-G1V3</b> as a promising candidate for the development of novel therapeutics against an ischemic stroke.
TL;DR
Collectively, these findings establish <b>c10c-G1V3</b> as a promising candidate for the development of novel therapeutics against an ischemic stroke.
Key findings
- Notably, it displayed superior plasma stability and favorable <i>in vivo</i> pharmacokinetic properties compared to <b>Tat-GluA2-3Y</b>.
- In SD rat tMCAO models, 8 mg/kg <b>c10c-G1V3</b> reduced infarct volume comparably to that of <b>Tat-GluA2-3Y</b>.
- Collectively, these findings establish <b>c10c-G1V3</b> as a promising candidate for the development of novel therapeutics against an ischemic stroke.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
To address this limitation, we systematically designed a series of <i>N</i>-methylated cyclic peptides derived from <b>GluA2-3Y</b> and identified the optimal peptide, <b>c10c-G1V3</b>, which exhibited high binding affinity for BRAG2 (<i>K</i><sub>d</sub> = 7.37 μM) and potent neuroprotective activity in both the OGD-induced cell model (cell viability: 85.97%) and the Glu-induced cell model (cell viability: 76.34%) at 10 μM. Mechanistically, <b>c10c-G1V3</b> markedly attenuated Glu-induced intracellular reactive oxygen species accumulation.
Full abstract (original)
Background: The membrane-permeable peptide <b>Tat-GluA2-3Y</b> exhibits therapeutic potential by competitively binding BRAG2 to disrupt GluA2 endocytosis. However, their poor <i>in vivo</i> stability has become a barrier to clinical application.
What they did: To address this limitation, we systematically designed a series of <i>N</i>-methylated cyclic peptides derived from <b>GluA2-3Y</b> and identified the optimal peptide, <b>c10c-G1V3</b>, which exhibited high binding affinity for BRAG2 (<i>K</i><sub>d</sub> = 7.37 μM) and potent neuroprotective activity in both the OGD-induced cell model (cell viability: 85.97%) and the Glu-induced cell model (cell viability: 76.34%) at 10 μM. Mechanistically, <b>c10c-G1V3</b> markedly attenuated Glu-induced intracellular reactive oxygen species accumulation.
Results & conclusions: Notably, it displayed superior plasma stability and favorable <i>in vivo</i> pharmacokinetic properties compared to <b>Tat-GluA2-3Y</b>. In SD rat tMCAO models, 8 mg/kg <b>c10c-G1V3</b> reduced infarct volume comparably to that of <b>Tat-GluA2-3Y</b>. Collectively, these findings establish <b>c10c-G1V3</b> as a promising candidate for the development of novel therapeutics against an ischemic stroke.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c02803 · PubMed 41708290.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Journal of Medicinal Chemistry for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Collectively, these findings establish <b>c10c-G1V3</b> as a promising candidate for the development of novel therapeutics against an ischemic stroke.
What type of study is this?
It is a research study, published in Journal of Medicinal Chemistry in 2026. To address this limitation, we systematically designed a series of <i>N</i>-methylated cyclic peptides derived from <b>GluA2-3Y</b> and identified the optimal peptide, <b>c10c-G1V3</b>, which exhibited high binding affinity for BRAG2 (<i>K</i><sub>d</sub> = 7.37 μM) and potent neuroprotective activity in both the OGD-induced cell model (cell viability: 85.97%) and the Glu-induced cell model (cell viability: 76.34%) at 10 μM.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.5c02803. PubMed ID: 41708290. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/discovery-of-stable-and-permeable-lt-i-gt-n-lt-i-gt-methylated-cyclic-pe-c02803/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides